NCT03512340View on ClinicalTrials.gov

Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

March 13, 2018

Primary Completion Date

September 15, 2020

Study Completion Date

September 29, 2020

Conditions
Advanced Solid CancersHematologic Cancers
Interventions
DRUG

SRF231

SRF231 specifically blocks the interaction between CD47 and signal regulatory protein alpha and acts as a potent enhancer of human tumor cell phagocytosis.

Trial Locations (3)

10065

Research Site 002, New York

78229

Research Site 001, San Antonio

M5G1Z5

Research Site 101, Toronto

Sponsors

Lead Sponsor

Surface Oncology
All Listed Sponsors
lead

Surface Oncology

INDUSTRY